New vaccine aims to train immune system against hepatitis b
NCT ID NCT06989788
First seen Apr 24, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This early-stage study tests a new vaccine called AVX70371 designed to treat chronic hepatitis B. Sixteen healthy adults aged 18 to 40 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe and can trigger the body's defenses against the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)
Ghent, Belgium
Conditions
Explore the condition pages connected to this study.